A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).
- EligibilityCriteria: Inclusion Criteria:  LDL >70md/dL Total coronary plaque > 75mm3 BMI 18-40 Max tolerated lipid modifying therapy eGFR greater/equal to 40  Exclusion Criteria: - HbA1c >10  Contraindications for CCTA History of coronary artery bypass graft Active liver disease - HealthyVolunteers: No - Gender: All - MinimumAge: 45 Years - StdAgeList: Adult, Older Adult